![Christopher Ogden](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 430 332 $ al 31/08/2026
Christopher Ogden is currently Chief Financial Officer, Secretary & Senior VP at CytomX Therapeutics, Inc. since 2021.
Former positions include Chief Financial Officer-Diabetes Division at Eli Lilly & Co. and Chief Financial Officer & Treasurer at Lilly del Caribe, Inc. Education includes an undergraduate degree from Wabash College and an MBA from Harvard Business School.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 15/06/2026 | 128.075 ( 0,08 % ) | 430 332 $ | 31/08/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| CYTOMX THERAPEUTICS, INC. | Director Financiero/CFO | 21/09/2022 |
| Empresas | Cargo | Fin |
|---|---|---|
Lilly del Caribe, Inc.
 Lilly del Caribe, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals | Director Financiero/CFO | - |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 5 |
|---|---|
Eli Lilly & Co.
 Eli Lilly & Co. Pharmaceuticals: MajorHealth Technology Manufactures, wholesales and markets pharmaceutical products | Health Technology |
Wabash College
 Wabash College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Lilly del Caribe, Inc.
Lilly del Caribe, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals | Health Technology |
Harvard Business School
 Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
CytomX Therapeutics, Inc.
 CytomX Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as an oncology-base biopharmaceutical company, which focuses on developing probody therapeutics for the treatment of cancer | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
